Cargando…

Bladder Cancer Immunotherapy: BCG and Beyond

Mycobacterium bovis bacillus Calmette-Guérin (BCG) has become the predominant conservative treatment for nonmuscle invasive bladder cancer. Its mechanism of action continues to be defined but has been shown to involve a T helper type 1 (Th1) immunomodulatory response. While BCG treatment is the curr...

Descripción completa

Detalles Bibliográficos
Autores principales: Askeland, Eric J., Newton, Mark R., O'Donnell, Michael A., Luo, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388311/
https://www.ncbi.nlm.nih.gov/pubmed/22778725
http://dx.doi.org/10.1155/2012/181987
_version_ 1782237168229416960
author Askeland, Eric J.
Newton, Mark R.
O'Donnell, Michael A.
Luo, Yi
author_facet Askeland, Eric J.
Newton, Mark R.
O'Donnell, Michael A.
Luo, Yi
author_sort Askeland, Eric J.
collection PubMed
description Mycobacterium bovis bacillus Calmette-Guérin (BCG) has become the predominant conservative treatment for nonmuscle invasive bladder cancer. Its mechanism of action continues to be defined but has been shown to involve a T helper type 1 (Th1) immunomodulatory response. While BCG treatment is the current standard of care, a significant proportion of patients fails or do not tolerate treatment. Therefore, many efforts have been made to identify other intravesical and immunomodulating therapeutics to use alone or in conjunction with BCG. This paper reviews the progress of basic science and clinical experience with several immunotherapeutic agents including IFN-α, IL-2, IL-12, and IL-10.
format Online
Article
Text
id pubmed-3388311
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-33883112012-07-09 Bladder Cancer Immunotherapy: BCG and Beyond Askeland, Eric J. Newton, Mark R. O'Donnell, Michael A. Luo, Yi Adv Urol Review Article Mycobacterium bovis bacillus Calmette-Guérin (BCG) has become the predominant conservative treatment for nonmuscle invasive bladder cancer. Its mechanism of action continues to be defined but has been shown to involve a T helper type 1 (Th1) immunomodulatory response. While BCG treatment is the current standard of care, a significant proportion of patients fails or do not tolerate treatment. Therefore, many efforts have been made to identify other intravesical and immunomodulating therapeutics to use alone or in conjunction with BCG. This paper reviews the progress of basic science and clinical experience with several immunotherapeutic agents including IFN-α, IL-2, IL-12, and IL-10. Hindawi Publishing Corporation 2012 2012-06-20 /pmc/articles/PMC3388311/ /pubmed/22778725 http://dx.doi.org/10.1155/2012/181987 Text en Copyright © 2012 Eric J. Askeland et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Askeland, Eric J.
Newton, Mark R.
O'Donnell, Michael A.
Luo, Yi
Bladder Cancer Immunotherapy: BCG and Beyond
title Bladder Cancer Immunotherapy: BCG and Beyond
title_full Bladder Cancer Immunotherapy: BCG and Beyond
title_fullStr Bladder Cancer Immunotherapy: BCG and Beyond
title_full_unstemmed Bladder Cancer Immunotherapy: BCG and Beyond
title_short Bladder Cancer Immunotherapy: BCG and Beyond
title_sort bladder cancer immunotherapy: bcg and beyond
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388311/
https://www.ncbi.nlm.nih.gov/pubmed/22778725
http://dx.doi.org/10.1155/2012/181987
work_keys_str_mv AT askelandericj bladdercancerimmunotherapybcgandbeyond
AT newtonmarkr bladdercancerimmunotherapybcgandbeyond
AT odonnellmichaela bladdercancerimmunotherapybcgandbeyond
AT luoyi bladdercancerimmunotherapybcgandbeyond